[EVALUATION OF THE BASIC PERFORMANCE IN THE SPECIFIC IGE ANTIBODY TEST KITS, VIEW ALLERGY 39 AND SILIS ALLERGY 45+1].

Kiwako Yamamoto-Hanada, Kenji Toyokuni, Miori Sato, Sayaka Hamaguchi, Fumi Ishikawa, Mayako Saito-Abe, Yasuaki Matsumoto, Hisako Ogasawara, Daichi Suzuki, Kotaro Umezawa, Hideaki Morita, Tatsuki Fukuie, Misao Oda, Shintaro Suzuki, Ken Fukuda, Takeshi Nakahara, Shigeharu Fujieda, Yukihiro Ohya
{"title":"[EVALUATION OF THE BASIC PERFORMANCE IN THE SPECIFIC IGE ANTIBODY TEST KITS, VIEW ALLERGY 39 AND SILIS ALLERGY 45+1].","authors":"Kiwako Yamamoto-Hanada, Kenji Toyokuni, Miori Sato, Sayaka Hamaguchi, Fumi Ishikawa, Mayako Saito-Abe, Yasuaki Matsumoto, Hisako Ogasawara, Daichi Suzuki, Kotaro Umezawa, Hideaki Morita, Tatsuki Fukuie, Misao Oda, Shintaro Suzuki, Ken Fukuda, Takeshi Nakahara, Shigeharu Fujieda, Yukihiro Ohya","doi":"10.15036/arerugi.73.1150","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>The aim of this study was to evaluate the basic performance and accuracy as a screening test by comparing SiLIS Allergy 45+1 with View Allergy 39.</p><p><strong>Methods: </strong>Measurements were performed with reagents and measuring instruments for View Allergy 39 and SiLIS Allergy 45+1 using blood samples of individuals with a previous history of IgE sensitizations. We compared the results between SiLIS Allergy 45+1 with View Allergy 39.</p><p><strong>Results: </strong>The agreement rates for positive, negative, judgment, and class of inhalant allergens were 88.7%, 95.1%, 90.8%, and 93.8%, respectively. The correlation rates for food allergens were 90.9%, 69.9%, 78.2%, and 89.2%, respectively. In triplicate measurements, the class agreement rate for SiLIS Allergy 45+1 was 94.2%. In correlation tests with previously approved drugs (FEIA method), the positive agreement rate for specific IgE was 94.9%, negative agreement rate was 95.0%, judgment agreement rate was 95.0%, and the class agreement rate for nonspecific IgE correlation tests was 100.0%, showing good results.</p><p><strong>Conclusion: </strong>Multi-item screening tests with SiLIS Allergy 45+1 showed high correlation with existing products such as View Allergy 39, suggesting high accuracy as a measurement method.</p>","PeriodicalId":35521,"journal":{"name":"Japanese Journal of Allergology","volume":"73 9","pages":"1150-1157"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15036/arerugi.73.1150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: The aim of this study was to evaluate the basic performance and accuracy as a screening test by comparing SiLIS Allergy 45+1 with View Allergy 39.

Methods: Measurements were performed with reagents and measuring instruments for View Allergy 39 and SiLIS Allergy 45+1 using blood samples of individuals with a previous history of IgE sensitizations. We compared the results between SiLIS Allergy 45+1 with View Allergy 39.

Results: The agreement rates for positive, negative, judgment, and class of inhalant allergens were 88.7%, 95.1%, 90.8%, and 93.8%, respectively. The correlation rates for food allergens were 90.9%, 69.9%, 78.2%, and 89.2%, respectively. In triplicate measurements, the class agreement rate for SiLIS Allergy 45+1 was 94.2%. In correlation tests with previously approved drugs (FEIA method), the positive agreement rate for specific IgE was 94.9%, negative agreement rate was 95.0%, judgment agreement rate was 95.0%, and the class agreement rate for nonspecific IgE correlation tests was 100.0%, showing good results.

Conclusion: Multi-item screening tests with SiLIS Allergy 45+1 showed high correlation with existing products such as View Allergy 39, suggesting high accuracy as a measurement method.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[特异性 ig 抗体检测试剂盒、view 过敏 39 和 silis 过敏 45+1 的基本性能评估]。
背景和目的:本研究旨在通过比较 SiLIS Allergy 45+1 和 View Allergy 39,评估其作为筛查试验的基本性能和准确性:方法:使用 View Allergy 39 和 SiLIS Allergy 45+1 的试剂和测量仪器,对曾有 IgE 过敏史的人的血样进行测量。我们比较了 SiLIS Allergy 45+1 和 View Allergy 39 的结果:结果:吸入剂过敏原的阳性、阴性、判断和类别的一致率分别为 88.7%、95.1%、90.8% 和 93.8%。食物过敏原的相关率分别为 90.9%、69.9%、78.2% 和 89.2%。在一式三份的测量中,SiLIS Allergy 45+1 的等级一致率为 94.2%。在与以前批准的药物(FEIA 方法)的相关测试中,特异性 IgE 的阳性一致率为 94.9%,阴性一致率为 95.0%,判断一致率为 95.0%,非特异性 IgE 相关测试的等级一致率为 100.0%,显示出良好的结果:SiLIS过敏45+1的多项目筛查测试与现有产品(如View Allergy 39)具有很高的相关性,表明其作为一种测量方法具有很高的准确性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Japanese Journal of Allergology
Japanese Journal of Allergology Medicine-Immunology and Allergy
CiteScore
0.30
自引率
0.00%
发文量
88
期刊介绍: The Japanese Society of Allergology is made up of medical researchers and clinical physicians who share an involvement in the study of allergies and clinical immunology. Clinical subspecialties include such allergies and immune-response disorders as bronchial asthma, hypersensitivity pneumonitis, collagen disease, allergic rhinitis, pollenosis, hives, atopic dermatitis, and immunodeficiency. However, there are many patients afflicted by other allergies as well. The Society considers all such patients and disorders within its purview.
期刊最新文献
[A CASE OF CLINICALLY AMYOPATHIC DERMAMYOSITIS WITH INTERSTITIAL LUNG DISEASE SHOWING TWO DETERIORATIONS IN 4 YEARS].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1